NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization340.12 mln
Float60.23 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
8.67
Transformational upside
Relative Strength
31
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-52.96
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Atea Pharmaceuticals is a Boston-based company focused on developing oral medicines to treat serious viral infections. Its most advanced treatment combines two drugs, bemnifosbuvir and ruzasvir, currently in late-stage clinical trials for hepatitis C, while a separate drug for chronic hepatitis E is in earlier testing. The company works with MSD International GmbH to develop and bring ruzasvir to market.
